OLIPASS Corporation (KOSDAQ:244460)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,651.00
-267.00 (-13.92%)
At close: Apr 7, 2025
Market Cap8.40B -57.2%
Revenue (ttm)5.25B +190.7%
Net Income-16.72B
EPS-5,043.35
Shares Out5.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume421,356
Average Volume398,769
Open1,650.00
Previous Close1,918.00
Day's Range1,568.00 - 2,080.00
52-Week Range1,568.00 - 9,250.00
Beta-0.43
RSI37.24
Earnings DateMay 15, 2026

About OLIPASS

OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD/DR; HIF-1a for chemo/radio-sensitizer treatment; Dystrophin for the treatment of duchenne muscular disease; and PTP1B for the treatment of type II dia... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2006
Employees 78
Stock Exchange KOSDAQ
Ticker Symbol 244460
Full Company Profile